(Q43892841)

27 November 2017

title

A cost-utility analysis of interventions for severe proliferative vitreoretinopathy (English)

1 reference

27 November 2017

Gary C Brown

1

1 reference

27 November 2017

Melissa M Brown

2

1 reference

27 November 2017

Sanjay Sharma

3

1 reference

27 November 2017

Brandon Busbee

4

1 reference

27 November 2017

Jennifer Landy

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

American Journal of Ophthalmology

27 November 2017

published in

1 reference

27 November 2017

volume

133

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

365-372

1 reference

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Evidence-based medicine, utilities, and quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Cost-effectiveness of treatment for threshold retinopathy of prematurity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Primer on Medical Decision Analysis: Part 2—Building a Tree

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Retinal Detachment in the Second Eye

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Bilateral rhegmatogenous retinal detachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Utility values and diabetic retinopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Utility values and age-related macular degeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Utilities and quality-adjusted life years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Adding insult to injury. Usurping patients' prerogatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Patients' preferences in randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Incorporating patients' preferences into medical decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Subjective and objective assessments of medical comorbidity in chronic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901423-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(01)01423-4

1 reference

27 November 2017

1 reference